Filter by country
Africa
Sao Tome and Principe
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Lesotho
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Cote d'Ivoire
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Angola
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
South-East Asia
Bangladesh
Bhutan
China
Korea, DPR
India
Indonesia
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by Category
Documents
Gavi Process Guidelines
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Russian
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
White papers
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
Annual Reports
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Board
Committee
Members
View by type:
Documents (9899)
Showing 12 of 9899
View All
Showing 752 of 825 pages
10 Chair s overview no paper pdf
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 10
12 -13 June 2012
Subject : Chair ?s overview
Agenda item : 10
No paper
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 10
12 -13 June 2012
Subject : Chair ?s overview
Agenda item : 10
No paper
11 Committee Chair reports no paper pdf
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 11
12 -13 June 2012
Subject : Committee Chair reports
Agenda item : 11
No paper
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 11
12 -13 June 2012
Subject : Committee Chair reports
Agenda item : 11
No paper
12 Options for enhancing GAVI s investment in measles prevention document pdf
1
Board -2012 -Mtg -2-Doc 12
Report to the
GAVI Alliance Board
12 -13 June 2012
Subject : Option s for enhancing GAVI?s investment in measles
prevention
Report of: Seth Berkley, Chief Executive Officer
Authored by: Alan Brooks , Senior Specialist, Policy & Performance , and
Nina Schwalbe , Managing Director, Policy & Performance
Agenda item : 12
Category: For Decision
Strategic goal : SG1 - Underused and new vaccines
Section A: Overview
1 Purpose of the report
1.1 In line with the conclusions of the Board retreat in Oslo in April, 2012, the
Secretariat has developed options and a recommendation to provide additional
financial support for measles vaccination in GAVI eligible countries .
2 Recommendations
2.1 The Secretariat recommends that the Board:
(a) Reques ts the Secretariat to put in place the necessary arrangements in
accordance with Annex 2, Option 2 of Document 12 , for six large
countries at high risk of measles outbreaks ( Afghanistan, Chad, DR
Congo, Ethiopia, Nigeria, and Pakistan) to be able to receiv e GAVI
support for measles vaccines and operational costs until these countries
are forecasted to have implemented a measles -rubella (MR) campaign,
or by no later than 2017. This support would be provided in collaboration
with the Measles & Rubella Initiat ive (MR Initiative, formerly the Measles
Initiative).
(b) Approv es US $ 55 million to be made available to the MR Initiative
through the UN Foundation for use through 2017 for outbreaks and other
emerging needs requiring rapid response s, using the mechanism
described in Annex 2 , Option 1 .
(c) Requests the Secretariat - given the importance of measles as an
indication of country support for routine immuni sation ? to develop an
indicator for measles first dose routine vaccine coverage as part of the
achievement of GAVI?s 2011 -2015 Strategy for review by the Evaluation
Advisory Committee .
Board -2012 -Mtg -2-Doc 12
Report to the
GAVI Alliance Board
12 -13 June 2012
Subject : Option s for enhancing GAVI?s investment in measles
prevention
Report of: Seth Berkley, Chief Executive Officer
Authored by: Alan Brooks , Senior Specialist, Policy & Performance , and
Nina Schwalbe , Managing Director, Policy & Performance
Agenda item : 12
Category: For Decision
Strategic goal : SG1 - Underused and new vaccines
Section A: Overview
1 Purpose of the report
1.1 In line with the conclusions of the Board retreat in Oslo in April, 2012, the
Secretariat has developed options and a recommendation to provide additional
financial support for measles vaccination in GAVI eligible countries .
2 Recommendations
2.1 The Secretariat recommends that the Board:
(a) Reques ts the Secretariat to put in place the necessary arrangements in
accordance with Annex 2, Option 2 of Document 12 , for six large
countries at high risk of measles outbreaks ( Afghanistan, Chad, DR
Congo, Ethiopia, Nigeria, and Pakistan) to be able to receiv e GAVI
support for measles vaccines and operational costs until these countries
are forecasted to have implemented a measles -rubella (MR) campaign,
or by no later than 2017. This support would be provided in collaboration
with the Measles & Rubella Initiat ive (MR Initiative, formerly the Measles
Initiative).
(b) Approv es US $ 55 million to be made available to the MR Initiative
through the UN Foundation for use through 2017 for outbreaks and other
emerging needs requiring rapid response s, using the mechanism
described in Annex 2 , Option 1 .
(c) Requests the Secretariat - given the importance of measles as an
indication of country support for routine immuni sation ? to develop an
indicator for measles first dose routine vaccine coverage as part of the
achievement of GAVI?s 2011 -2015 Strategy for review by the Evaluation
Advisory Committee .
13 Vaccine introduction grants and operation support for campaigns document pdf
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 13
12 -13 June 2012
Subject : Vaccine introduction grants and operational support
for campaigns
Report of: Nina Schwalbe, M anaging Director, Policy & Performance
Authored by: Aur?lia Nguyen, Director, Policy & Market Shaping; and
Eliane Furrer , Senior Programme Officer, Policy
Agenda item : 13
Category: For Decision
Strategic goal : SG1 - Underused and new vaccines
Section A: Overview
1. Purpose of the repor t
1.1 This report presents the recommended revisions to GAVI?s vaccine
introduction grant policy and GAVI?s operational support for campaigns,
including proposed levels of support and their financial implications. The
Programme and Policy Committee (PPC) endorsed the policy to the Board in
its meeting on 23 -24 April 2012.
2. Recommendations
2.1 The PPC recommends that the GAVI Alliance Board :
? Approve the GAVI vaccine introduction grant and operational support for
campaigns policy (the ? Policy ?), as described in Annex 1 of Doc 13;
? Request the Secretariat to make the necessary arrangements to ensure
that vaccine introductions and campaigns occurring on or after 1
September 2012 benefit from the Policy regardless of when th e country
proposal was approved .
3. Executive summary
3.1 Consultations concluded that v accine introduction grants have been
appreciated by countries and, when disbursed in a timely manner, are seen as
critical to successful vaccine introduction. Likewise, GAVI?s operationa l support
to campaigns has facilitated implementation of campaigns and contributed to
increased planning certainty for countries. However, f eedback from countries
and partners indicate that the current policies in place for these two types of
cash support h ave some major weaknesses , which the current revision
attempts to address .
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 13
12 -13 June 2012
Subject : Vaccine introduction grants and operational support
for campaigns
Report of: Nina Schwalbe, M anaging Director, Policy & Performance
Authored by: Aur?lia Nguyen, Director, Policy & Market Shaping; and
Eliane Furrer , Senior Programme Officer, Policy
Agenda item : 13
Category: For Decision
Strategic goal : SG1 - Underused and new vaccines
Section A: Overview
1. Purpose of the repor t
1.1 This report presents the recommended revisions to GAVI?s vaccine
introduction grant policy and GAVI?s operational support for campaigns,
including proposed levels of support and their financial implications. The
Programme and Policy Committee (PPC) endorsed the policy to the Board in
its meeting on 23 -24 April 2012.
2. Recommendations
2.1 The PPC recommends that the GAVI Alliance Board :
? Approve the GAVI vaccine introduction grant and operational support for
campaigns policy (the ? Policy ?), as described in Annex 1 of Doc 13;
? Request the Secretariat to make the necessary arrangements to ensure
that vaccine introductions and campaigns occurring on or after 1
September 2012 benefit from the Policy regardless of when th e country
proposal was approved .
3. Executive summary
3.1 Consultations concluded that v accine introduction grants have been
appreciated by countries and, when disbursed in a timely manner, are seen as
critical to successful vaccine introduction. Likewise, GAVI?s operationa l support
to campaigns has facilitated implementation of campaigns and contributed to
increased planning certainty for countries. However, f eedback from countries
and partners indicate that the current policies in place for these two types of
cash support h ave some major weaknesses , which the current revision
attempts to address .
14 Continued funding for special studies document pdf
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 14
12 -13 June 2012
Subject : Continued f unding for special s tudies
Report of: Nina Schwalbe, Managing Director, Policy & Performance
Authored by: Ciara Goldstein , Analyst, Policy and Performance and
Peter Hansen, Director, Monitoring & Evaluation
Agenda item : 14
Category: For Decision
Strategic goal : SG1 - Vaccines & SG2 - Health systems
Section A: Overview
1. Purpose of the repor t
1.1 This paper outlines a request for urgent funding for continui ng research studies
submitted by the Accelerated Vaccine Introduction Initiative Technical
Assistance Consortium (AVI -TAC).
2. Recommendations
2.1 The PPC reviewed four urgent special studies proposals from AVI -TAC and
recommended that the GAVI Alliance Board:
? Approve an amount of up to US$ 9.3 million for AVI -TAC to continue two
urgent pneumococcal studies and conduct two urgent rotavirus stud ies
over a three year period, through 2015 .
2.2 In connection with these four urgent studies, the PPC noted that consideration
should be given to the impact of the recent SAGE recommendation to loosen
the age restrictions for the delivery of rotavirus vaccines. To enable an
assessment of this impact , in parallel with the four urgent studies , and
following the PPC, the Secretariat recommends that the Board:
Approve , subject to the Secretariat receiving satisfactory peer review
reports, an amount of US$ 1.8 million for AVI -TAC to conduct a study to
monit or the impact of the SAGE recommendation on widening age
restrictions related to rotavirus vaccine delivery.
3. Executive summary
3.1 The AVI -TAC Special Studies sub -team has identified urgent priority needs
and submitted four study proposals to GAVI in February 2012. Because of the
imperative to address these mission critical questions in a timely manner,
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 14
12 -13 June 2012
Subject : Continued f unding for special s tudies
Report of: Nina Schwalbe, Managing Director, Policy & Performance
Authored by: Ciara Goldstein , Analyst, Policy and Performance and
Peter Hansen, Director, Monitoring & Evaluation
Agenda item : 14
Category: For Decision
Strategic goal : SG1 - Vaccines & SG2 - Health systems
Section A: Overview
1. Purpose of the repor t
1.1 This paper outlines a request for urgent funding for continui ng research studies
submitted by the Accelerated Vaccine Introduction Initiative Technical
Assistance Consortium (AVI -TAC).
2. Recommendations
2.1 The PPC reviewed four urgent special studies proposals from AVI -TAC and
recommended that the GAVI Alliance Board:
? Approve an amount of up to US$ 9.3 million for AVI -TAC to continue two
urgent pneumococcal studies and conduct two urgent rotavirus stud ies
over a three year period, through 2015 .
2.2 In connection with these four urgent studies, the PPC noted that consideration
should be given to the impact of the recent SAGE recommendation to loosen
the age restrictions for the delivery of rotavirus vaccines. To enable an
assessment of this impact , in parallel with the four urgent studies , and
following the PPC, the Secretariat recommends that the Board:
Approve , subject to the Secretariat receiving satisfactory peer review
reports, an amount of US$ 1.8 million for AVI -TAC to conduct a study to
monit or the impact of the SAGE recommendation on widening age
restrictions related to rotavirus vaccine delivery.
3. Executive summary
3.1 The AVI -TAC Special Studies sub -team has identified urgent priority needs
and submitted four study proposals to GAVI in February 2012. Because of the
imperative to address these mission critical questions in a timely manner,
15 Programme Update Accelerated Vaccine Introduction pdf
1
Report of the
GAVI Alliance Board
12 -13 June 2012
Board -2012 -Mtg -2-Doc 15
Subject : Programme update : Accelerated Vaccine Introduction
Report of: Seth Berkley, Chief Executive Officer
Authored by: Jon Pearman, Senior Technical Advisor, Vaccines
Agenda item : 15
Category: For Information
Strategic goal : SG1 - Vaccines & SG4 - Market shaping
Section A: Overview
1 Purpose of the report
1.1 The purpose of this report is to provide a summary on the progress of new
vaccine rollout supported by the Accelerated Vaccine Introduction (AVI)
initiative and progress toward building a platform for future introductions.
2 Recommendations
2.1 For information only.
3 Executive Summary
3.1 Pneumococcal and rotavirus vaccines :
(a) In 2012, the GAVI Alliance marked the first simultaneous introduction of
both pneumococcal and rotavirus vaccines in Ghana in April. Nine
additional countries are expected to launch pneumococcal vaccines
(bringing the total to 10) and another seven are planned to introduce
rotavirus vaccines (bring ing the total to 8) this year. As reported to the
Board in Dhaka, however, unprecedented levels of demand for the two
vaccines that exceeds available supply will lead to delays in a number of
countries, at this point in time anticipated to affect mainly 2013.
(b) The supply situation remains dynamic. For example, since AVI?s recent
update to the Programme and Policy Committee (PPC) in April, one
manufacturer has confirmed the availability of additional quantities of
pneumococcal vaccines (PCV). Furthermore, the WHO has approved the
expanded use of the novel two dose PCV presentation with special
requirements. Both of these developments could ease supply constraints
for pneumococcal vaccines in 2012 and 2013 (see Annex 1 for details).
Report of the
GAVI Alliance Board
12 -13 June 2012
Board -2012 -Mtg -2-Doc 15
Subject : Programme update : Accelerated Vaccine Introduction
Report of: Seth Berkley, Chief Executive Officer
Authored by: Jon Pearman, Senior Technical Advisor, Vaccines
Agenda item : 15
Category: For Information
Strategic goal : SG1 - Vaccines & SG4 - Market shaping
Section A: Overview
1 Purpose of the report
1.1 The purpose of this report is to provide a summary on the progress of new
vaccine rollout supported by the Accelerated Vaccine Introduction (AVI)
initiative and progress toward building a platform for future introductions.
2 Recommendations
2.1 For information only.
3 Executive Summary
3.1 Pneumococcal and rotavirus vaccines :
(a) In 2012, the GAVI Alliance marked the first simultaneous introduction of
both pneumococcal and rotavirus vaccines in Ghana in April. Nine
additional countries are expected to launch pneumococcal vaccines
(bringing the total to 10) and another seven are planned to introduce
rotavirus vaccines (bring ing the total to 8) this year. As reported to the
Board in Dhaka, however, unprecedented levels of demand for the two
vaccines that exceeds available supply will lead to delays in a number of
countries, at this point in time anticipated to affect mainly 2013.
(b) The supply situation remains dynamic. For example, since AVI?s recent
update to the Programme and Policy Committee (PPC) in April, one
manufacturer has confirmed the availability of additional quantities of
pneumococcal vaccines (PCV). Furthermore, the WHO has approved the
expanded use of the novel two dose PCV presentation with special
requirements. Both of these developments could ease supply constraints
for pneumococcal vaccines in 2012 and 2013 (see Annex 1 for details).
17 GAVI support to Civil Society Organisations document pdf
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 17
12 -13 June 2012
Subject : GAVI Support to Civil Society Organisation s
Report of: Paul Kelly, Director Country Support , Coutry programme
Authored by: Paul Kelly
Agenda item : 17
Category: For Decision
Strategic goal : SG2 - Health systems to deliver immunisation
Section A: Overview
1. Purpose of the repor t
1.1 In July 2011 the GAVI Board ? requested the Secretariat, concurrently with the
evaluation of CSO support in 2011, to review options for direct support to CSOs
for service delivery and advocacy and submit to the PPC for its recommendation
to the Board ?. This paper presents the PPC recommendation for decision.
2. Recommendations
2.1 The Programme and Policy Committee recommend s that the GAVI Alliance Board:
? Decide that Government remains the default approach but direct funding for
CSO activities can be requested as part of a country Health Systems Funding
Platform (HSFP) application (Option 3).
While provision of funds to CSOs through the HSFP is the recommended
option, it should not limit GAVI?s flexibility to engage CSOs directly where
rare and exceptional circumstances require different approaches.
Approaches should be developed in response to country -specific analysis.
? Re quest the Secretariat to prepare an implementation framework
recognising an increased risk in procurement and financial management and
potential resource implications for the Secretariat and whic h draws on the
findings of the E valuation of GAVI support to CSOs and presents why and
how GAVI works with and supports CSOs.
3. Executive summary
3.1 At the July 2011 Board meeting, GAVI?s Civil Society Cons tituency expressed
concern that slow disbursement of GAVI funds for CSO Type B activities was
causing disruption to program implementation and undermining effectiveness.
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 17
12 -13 June 2012
Subject : GAVI Support to Civil Society Organisation s
Report of: Paul Kelly, Director Country Support , Coutry programme
Authored by: Paul Kelly
Agenda item : 17
Category: For Decision
Strategic goal : SG2 - Health systems to deliver immunisation
Section A: Overview
1. Purpose of the repor t
1.1 In July 2011 the GAVI Board ? requested the Secretariat, concurrently with the
evaluation of CSO support in 2011, to review options for direct support to CSOs
for service delivery and advocacy and submit to the PPC for its recommendation
to the Board ?. This paper presents the PPC recommendation for decision.
2. Recommendations
2.1 The Programme and Policy Committee recommend s that the GAVI Alliance Board:
? Decide that Government remains the default approach but direct funding for
CSO activities can be requested as part of a country Health Systems Funding
Platform (HSFP) application (Option 3).
While provision of funds to CSOs through the HSFP is the recommended
option, it should not limit GAVI?s flexibility to engage CSOs directly where
rare and exceptional circumstances require different approaches.
Approaches should be developed in response to country -specific analysis.
? Re quest the Secretariat to prepare an implementation framework
recognising an increased risk in procurement and financial management and
potential resource implications for the Secretariat and whic h draws on the
findings of the E valuation of GAVI support to CSOs and presents why and
how GAVI works with and supports CSOs.
3. Executive summary
3.1 At the July 2011 Board meeting, GAVI?s Civil Society Cons tituency expressed
concern that slow disbursement of GAVI funds for CSO Type B activities was
causing disruption to program implementation and undermining effectiveness.
18 Long term funding strategy document pdf
J
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 18 1
12 -13 June 2012
Subject: Long -term funding strategy
Report of: Joelle Tanguy, M anaging Director , External Relations and
David Ferreira, M anaging Director , Innovative Finance
Authored by: Marie -Ange Saraka -Yao and Programme Funding Team,
Tony Dutson, Kim Hartmann, Geoff Adlide, Jeffrey Rowland,
with Joelle Tanguy and David Ferreira
Agenda item: 18
Category: For Guidance/Discussion
Strategic goal: SG3 - Financing
Section A: Overview
1. Purpose of the report
1.1 The following initial directions for GAVI?s long -term funding model and
strategy are submitted to the GAVI Board for discussion and feedback. A
long -term funding strategy will be presented to the Board in December 2012
for decision .
2. Recommend ations
2.1 The Board is asked to discuss the key elements and provide guidance to
the Secretariat on (i) the long -term funding model and capital structure, (ii)
burden -sharing directions , and (iii) diversification strategy.
3 Executive summary
3.1 This paper identifies the key priorities of the long -term funding strategy and
presents a roadmap for the replenishment process while building on lessons
learned from the first replenishment .
3.2 The Secretariat proposes that GAVI?s long -term funding strategy focus on the
following three priorities:
(a) Building a long -term funding model that will support a mix of funding
mechanisms that can deliver the predictable and efficient funding required
to meet GAVI?s resource needs .
(b) Moving toward sustainable burden -shar ing with a diversified donor base
complemented by firm co -financing commitments f rom countries and
active market -shaping .
(c) Supporting more predictable replenishment through a four -phase
consensus -building process.
3.3 The Board?s view and guidance is requested regarding:
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 18 1
12 -13 June 2012
Subject: Long -term funding strategy
Report of: Joelle Tanguy, M anaging Director , External Relations and
David Ferreira, M anaging Director , Innovative Finance
Authored by: Marie -Ange Saraka -Yao and Programme Funding Team,
Tony Dutson, Kim Hartmann, Geoff Adlide, Jeffrey Rowland,
with Joelle Tanguy and David Ferreira
Agenda item: 18
Category: For Guidance/Discussion
Strategic goal: SG3 - Financing
Section A: Overview
1. Purpose of the report
1.1 The following initial directions for GAVI?s long -term funding model and
strategy are submitted to the GAVI Board for discussion and feedback. A
long -term funding strategy will be presented to the Board in December 2012
for decision .
2. Recommend ations
2.1 The Board is asked to discuss the key elements and provide guidance to
the Secretariat on (i) the long -term funding model and capital structure, (ii)
burden -sharing directions , and (iii) diversification strategy.
3 Executive summary
3.1 This paper identifies the key priorities of the long -term funding strategy and
presents a roadmap for the replenishment process while building on lessons
learned from the first replenishment .
3.2 The Secretariat proposes that GAVI?s long -term funding strategy focus on the
following three priorities:
(a) Building a long -term funding model that will support a mix of funding
mechanisms that can deliver the predictable and efficient funding required
to meet GAVI?s resource needs .
(b) Moving toward sustainable burden -shar ing with a diversified donor base
complemented by firm co -financing commitments f rom countries and
active market -shaping .
(c) Supporting more predictable replenishment through a four -phase
consensus -building process.
3.3 The Board?s view and guidance is requested regarding:
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 19
12 -13 June 2012
Subject : IFFIm report
Agenda item : 19
No paper
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 19
12 -13 June 2012
Subject : IFFIm report
Agenda item : 19
No paper
20 IFFIm GFA restructuring document pdf
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 20
12 -13 June 2012
Subject : IFFIm/GFA restructuring
Report of: Debbie Adams, Managing Director, Law & Governance
Authored by: Anthony Brown, Senior Legal Counsel , and
Louis Mkanganwi, Director of Financial Reporting
Agenda item : 20
Category: For Decision
Strategi c goal : Alliance operations
Section A: Overview
1. Purpose of the repor t
1.1 This report updates the GAVI Alliance Board on progress made since the
report presented to the Board at its meeting in November 2011 on the removal
of the GAVI Fund Affiliate (? GFA ?) from the IFFIm structure and sets out a
recommendation for the Board in relation to GAVI undertaking to perform
GFA?s major responsibility under the IFFIm Agreements .1
2. Recommendations
2.1 The GAVI Board is requested to:
(a) Approve GAVI entering into any new grant agreements with the IFFI m
donors once the Finance Framework Agreement (?FFA ?) is amended to
remove the GFA from the IFFIm structure; and
(b) Approve the immediate assignment to the IFFIm Company of any new
grant agreements entered into between GAVI and the IFFIm d onors .
3. Executive summary
3.1 The Secretariat presented at the GAVI Board meeting in November 2011 its
initial analysis on the proposal to remove GFA from the IFFIm structure . That
work is now complete and it is confirmed that there are no legal, tax or
accounting impediments to removing GFA. In addition, we have consulted with
most of the donors to IFFIm and they have expressed support for this change.
Once GFA is removed from the IFFIm structure , the donors have expressed a
preference that GFA?s major responsibility of entering in to grant agreements
with IFFIm d onors should be assigned to GAVI (rather than to IFFIm directly)
1 The IFFIm Agreements includes, among others, the Finance Framework Agreement, Procedures
Memorandum and the Master Defini tions Agreement.
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc 20
12 -13 June 2012
Subject : IFFIm/GFA restructuring
Report of: Debbie Adams, Managing Director, Law & Governance
Authored by: Anthony Brown, Senior Legal Counsel , and
Louis Mkanganwi, Director of Financial Reporting
Agenda item : 20
Category: For Decision
Strategi c goal : Alliance operations
Section A: Overview
1. Purpose of the repor t
1.1 This report updates the GAVI Alliance Board on progress made since the
report presented to the Board at its meeting in November 2011 on the removal
of the GAVI Fund Affiliate (? GFA ?) from the IFFIm structure and sets out a
recommendation for the Board in relation to GAVI undertaking to perform
GFA?s major responsibility under the IFFIm Agreements .1
2. Recommendations
2.1 The GAVI Board is requested to:
(a) Approve GAVI entering into any new grant agreements with the IFFI m
donors once the Finance Framework Agreement (?FFA ?) is amended to
remove the GFA from the IFFIm structure; and
(b) Approve the immediate assignment to the IFFIm Company of any new
grant agreements entered into between GAVI and the IFFIm d onors .
3. Executive summary
3.1 The Secretariat presented at the GAVI Board meeting in November 2011 its
initial analysis on the proposal to remove GFA from the IFFIm structure . That
work is now complete and it is confirmed that there are no legal, tax or
accounting impediments to removing GFA. In addition, we have consulted with
most of the donors to IFFIm and they have expressed support for this change.
Once GFA is removed from the IFFIm structure , the donors have expressed a
preference that GFA?s major responsibility of entering in to grant agreements
with IFFIm d onors should be assigned to GAVI (rather than to IFFIm directly)
1 The IFFIm Agreements includes, among others, the Finance Framework Agreement, Procedures
Memorandum and the Master Defini tions Agreement.
1
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc A
12 -13 June 2012
Subject : India strategy update
Report of: Seth Berkley, Chief Executive Officer
Authored by: Ranjana Kumar, Senior Specialist , Country Programmes
Agenda item : A
Category: For Information
Strategic goal : Affects all strategic goals
Section A: Overview
1. Purpose of the repor t
1.1 The purpose of this report is to update the Board on the progress with regard to the
development of a customised strategy for India.
2. Recommendations
2.1 The paper is for information only. A detailed paper with financial implications will be
presented to the Executive Committee for approval later in the year.
3. Executive summary
3.1 This is an exciting phase for the GAVI -India relationship . Since the GAVI Board
meeting in November 2011, we have stepped up our engagement with India. Buoyed
by the success in interrupting polio transmission, India is demonstrating a new vigour
in its commitment to strengthening its immunisation programme.
3.2 Given India?s size and the scale of its own resources, GAVI?s approach continues to
be catalytic, with an emphasis on working with India to enhance the ambition and
effectiveness of India?s own immunisation programme.
3.3 Currently India is working on a reque st for GAVI support to strengthen the health
systems in weaker states thus enabling them to scale up pentavalent vaccines
nationally. A subsequent request for catalytic support to introduce measles -rubella
vaccine is expected. The decision to introduce pne umococcal and rotavirus vaccines
will be based on the successful outcome of clinical trials and other debates currently
underway in India, partial ly supported by GAVI partners. We are closely following
these activities and have offered to assist in any wa y we are able, including support if
necessary.
3.4 India will also continue to be a priority for GAVI?s market shaping strategy which will
include advocating for the strengthening of the National Regulatory Authority (NRA)
and encouraging the entry of manufac turers to supply current and potential future
GAVI -supported vaccines.
Report to the
GAVI Alliance Board
Board -2012 -Mtg -2-Doc A
12 -13 June 2012
Subject : India strategy update
Report of: Seth Berkley, Chief Executive Officer
Authored by: Ranjana Kumar, Senior Specialist , Country Programmes
Agenda item : A
Category: For Information
Strategic goal : Affects all strategic goals
Section A: Overview
1. Purpose of the repor t
1.1 The purpose of this report is to update the Board on the progress with regard to the
development of a customised strategy for India.
2. Recommendations
2.1 The paper is for information only. A detailed paper with financial implications will be
presented to the Executive Committee for approval later in the year.
3. Executive summary
3.1 This is an exciting phase for the GAVI -India relationship . Since the GAVI Board
meeting in November 2011, we have stepped up our engagement with India. Buoyed
by the success in interrupting polio transmission, India is demonstrating a new vigour
in its commitment to strengthening its immunisation programme.
3.2 Given India?s size and the scale of its own resources, GAVI?s approach continues to
be catalytic, with an emphasis on working with India to enhance the ambition and
effectiveness of India?s own immunisation programme.
3.3 Currently India is working on a reque st for GAVI support to strengthen the health
systems in weaker states thus enabling them to scale up pentavalent vaccines
nationally. A subsequent request for catalytic support to introduce measles -rubella
vaccine is expected. The decision to introduce pne umococcal and rotavirus vaccines
will be based on the successful outcome of clinical trials and other debates currently
underway in India, partial ly supported by GAVI partners. We are closely following
these activities and have offered to assist in any wa y we are able, including support if
necessary.
3.4 India will also continue to be a priority for GAVI?s market shaping strategy which will
include advocating for the strengthening of the National Regulatory Authority (NRA)
and encouraging the entry of manufac turers to supply current and potential future
GAVI -supported vaccines.
Annex Board Committee minutes pdf
Board -2012 -Mtg -2-Annex: Committee minutes
GAVI Alliance Board Meeting
12 -13 June 2012
Capital Hilton Hotel, Washington, DC, USA
Sunday 10 and Monday 11 June: Pre -Board meetings
Tuesday 12 June: 08.30 -18.15 (Board meeting Day One)
Wednesday 13 June: 08.30 -17.00 (Board meeting Day Two)
Thursday 14 June: Post -Board meetings
Annex: Committee minutes
Annex Pages MINUTES
1-9 - Executive Committee ? 9 March 2012
10 -20 - Audit and Finance Committee ? 11 April 2012
21 -27 - Evaluation Advisory Committee ? 19 -20 January 2012
28 -29 - Evaluation Advisory Committee ? 13 February 2012
30-33 - Governance Committee ? 10 April 2012
34 -43 - Governance Committee ? 14 May 2012 (Decision slides)
44 -46 - Investment Committee ? 28 March 2012
47 -49 - Investment Committee ? 24 May 2012
50 -54 - Programme and Policy Committee ? 23 -24 April 2012 (Decision slides)
Note: Minutes of Committee meetings since Dhaka are included for ease of
reference. The Programme and Policy Committe e minutes from 23 -24 April 2012
and the Governance Committee minutes from 14 May 2012 are not yet approved .
However, their decision slides are attached for information.